Abstract:The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused both a health and economic crisis around the world. Its papain-like protease (PLpro) is one of the protein targets utilized in designing new drugs that would aid vaccines in the fight against the virus. Although there are already several potential candidates for a good inhibitor of this protein, the degree of variability of the protein itself is not taken into account. As an RNA virus, SARS-CoV-2 can mutate to a high degree, but PLpro variability has not been studied to date. Based on sequence data available in databases, we analyzed the mutational potential of this protein. We focused on the effect of observed mutations on inhibitors' binding mode and their efficacy as well as protein's activity. Our analysis identifies five mutations that should be monitored and included in the drug design process: P247S, E263D-Y264H and T265A-Y268C. Antiviral drugs often work by tightly fitting into a viral protein and interfering with its function. However, viruses can evolve at a high rate and even a single amino acid change in the binding pocket can greatly disrupt protein-ligand interactions and decrease drug's efficiency. Currently, one of the most important viruses is the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for a global health and economical crisis. Here, we demonstrate how naturally-occurring mutations of SARS-CoV-2 papain-like protease (PLpro) reduce the effectiveness of existing inhibitors. First, we employ theoretical calculations of mutations' impact and identify seven most important changes which we then assess by more computationally expensive simulation techniques. Later, we confirm the results by an in vitro enzymatic assay. In this way, we identify five mutations that reduce the drug effectiveness. At the same time, some of them increase the native PLpro activity. These two facts suggest that the identified genetic variants should be taken into account for designing and testing new SARS-CoV-2 drugs.

Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors

REVISITING THE SARS-COV-2 MAIN PROTEASE: A 2023 IN SILICO ODYSSEY IN SEARCH OF POTENTIAL INHIBITORS

A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system

Systematic Analyses of the Resistance Potential of Drugs Targeting SARS-CoV-2 Main Protease

Recent changes in the mutational dynamics of the SARS-CoV-2 main protease substantiate the danger of emerging resistance to antiviral drugs

Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains

Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance

Targeting Viral and Cellular Cysteine Proteases for Treatment of New Variants of SARS-CoV-2

Structural and virologic mechanism of the emergence of resistance to Mpro inhibitors in SARS-CoV-2

Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir

Highly specific SARS-CoV-2 main protease (Mpro) mutations against the clinical antiviral ensitrelvir selected in a safe, VSV-based system

Targeting SARS-CoV-2 Proteases for COVID-19 Antiviral Development

Molecular Mechanisms of SARS-CoV-2 Resistance to Nirmatrelvir

New Thiazolidine-4-One Derivatives as SARS-CoV-2 Main Protease Inhibitors

Integrative Approach to Dissect the Drug Resistance Mechanism of the H172Y Mutation of SARS-CoV-2 Main Protease

Design of novel and highly selective SARS-CoV-2 main protease inhibitors

Amino acid variants of SARS-CoV-2 papain-like protease have impact on drug binding

Effects of SARS-CoV-2 Main Protease Mutations at Positions L50, E166, and L167 Rendering Resistance to Covalent and Noncovalent Inhibitors

The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022

Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease